{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T13:24:02Z","timestamp":1787405042709,"version":"build-2736575974"},"reference-count":55,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Diabetic kidney disease (DKD) now has more proven kidney-protective therapies than at any previous time: renin\u2013angiotensin system inhibitors (RASi), sodium\u2013glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and the nonsteroidal mineralocorticoid receptor antagonist (nsMRA) finerenone. However, no head-to-head randomized controlled trial (RCT) has compared these classes, no Phase 3 trial has confirmed that specific multi-class combinations improve hard outcomes beyond well-selected monotherapy; and long-term safety of sustained combination therapy has not been fully characterized. This review synthesizes contemporary evidence for kidney-protective therapy in adults with DKD, emphasizing that non-pharmacologic measures\u2014blood pressure control, individualized glycemic targets, sodium and protein moderation, structured exercise, weight management, and smoking cessation\u2014should be intensified concurrently with drug therapy. We propose an individualization framework that selects agents whose mechanisms address more than one of the patient\u2019s clinical problems simultaneously and avoids those whose adverse effects conflict with active comorbidities. Combination therapy is biologically rational and supported by additive albuminuria reduction (CONFIDENCE) and lifetime modeling, but hard-outcome confirmation is absent. Until such trials are available, the most defensible framework is an individualized, monitoring-based strategy that adapts through addition, hold, or deprescribing based on clinical evolution.<\/jats:p>","DOI":"10.1093\/ndt\/gfag179","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:11:26Z","timestamp":1786101086000},"source":"Crossref","is-referenced-by-count":0,"title":["Individualizing pharmacologic and non-pharmacologic therapy for chronic kidney disease associated with diabetes"],"prefix":"10.1093","author":[{"given":"Zurong","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Nephrology, the Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification , Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, the Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification , Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, the Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification , Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, the Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification , Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, the Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification , Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nephrology, the Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification , Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-7100","authenticated-orcid":false,"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Richard L. Roudebush VA Medical Center, and Indiana University School of Medicine , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"2026082209063216200_bib1","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026082209063216200_bib2","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026082209063216200_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2026082209063216200_bib4","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026082209063216200_bib5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026082209063216200_bib6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026082209063216200_bib7","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026082209063216200_bib8","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026082209063216200_bib9","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026082209063216200_bib10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2026082209063216200_bib11","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"KDIGO","year":"2022","journal-title":"Kidney Int"},{"key":"2026082209063216200_bib12","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"KDIGO","year":"2024","journal-title":"Kidney Int"},{"key":"2026082209063216200_bib13","doi-asserted-by":"publisher","first-page":"S246","DOI":"10.2337\/dc26-S011","article-title":"Chronic kidney disease and risk management: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"2026082209063216200_bib14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41581-024-00827-z","article-title":"Combination therapy for kidney disease in people with diabetes mellitus","volume":"20","author":"van\u00a0Raalte","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"2026082209063216200_bib15","doi-asserted-by":"publisher","first-page":"e1726","DOI":"10.1210\/clinem\/dgag163","article-title":"Combination treatment for management of chronic kidney disease and type 2 diabetes: a review and practical guidance","volume":"111","author":"Mohsen","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"2026082209063216200_bib16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/jamainternmed.2025.7409","article-title":"SGLT2 inhibitors vs GLP-1 receptor agonists for kidney outcomes in individuals with type 2 diabetes","volume":"186","author":"Jensen","year":"2026","journal-title":"JAMA Intern Med"},{"key":"2026082209063216200_bib17","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the combination effect of finerenone and empagliflozin in participants with chronic kidney disease and type 2 diabetes using a UACR endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026082209063216200_bib18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026082209063216200_bib19","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2026.01.010","article-title":"Acute estimated glomerular filtration rate decline after initiation of therapies that slow kidney disease progression: clinical practice implications","author":"Cherney","year":"2026","journal-title":"Mayo Clin Proc"},{"key":"2026082209063216200_bib20","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/ndt\/gfag003","article-title":"Trends in nephrology: from \"supportive care\" to CKD combination therapy","volume":"41","author":"He","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"2026082209063216200_bib21","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/ndt\/gfae212","article-title":"Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease","volume":"40","author":"Alicic","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026082209063216200_bib22","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1111\/dom.15194","article-title":"Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019\u20132020","volume":"25","author":"Nicholas","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026082209063216200_bib23","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.1111\/dom.16608","article-title":"Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: analysis of an Australian primary care dataset","volume":"27","author":"Wallace","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026082209063216200_bib24","doi-asserted-by":"publisher","first-page":"102642","DOI":"10.1016\/j.jacadv.2026.102642","article-title":"Finerenone utilization for chronic kidney disease and diabetes: multicenter real-world study in the United States","volume":"5","author":"Lin","year":"2026","journal-title":"JACC Adv"},{"key":"2026082209063216200_bib25","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacc.2025.10.049","article-title":"Risk of hyperkalemia with empagliflozin, finerenone, or both: secondary analysis of the CONFIDENCE randomized trial","volume":"87","author":"Agarwal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"2026082209063216200_bib26","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","article-title":"Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation"},{"key":"2026082209063216200_bib27","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.jacc.2024.01.040","article-title":"Genitourinary tract infections in patients taking SGLT2 inhibitors: JACC review topic of the week","volume":"83","author":"Kittipibul","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026082209063216200_bib28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2026082209063216200_bib29","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: improving Global Outcomes (KDIGO)","volume":"102","author":"de\u00a0Boer","year":"2022","journal-title":"Kidney Int"},{"key":"2026082209063216200_bib30","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","article-title":"Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomized trial","volume":"59","author":"G\u00e6de","year":"2016","journal-title":"Diabetologia"},{"key":"2026082209063216200_bib31","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1161\/HYP.0000000000000087","article-title":"Measurement of blood pressure in humans: a scientific statement from the American Heart Association","volume":"73","author":"Muntner","year":"2019","journal-title":"Hypertension"},{"key":"2026082209063216200_bib32","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"2026082209063216200_bib33","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/joim.20078","article-title":"Systolic blood pressure targets below 120 mm Hg are associated with reduced mortality: a meta-analysis","volume":"297","author":"Bergmann","year":"2025","journal-title":"J Intern Med"},{"key":"2026082209063216200_bib34","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.2337\/dc26-S013","article-title":"Standards of care in diabetes-2026","volume":"49","author":"Older","year":"2026","journal-title":"Diabetes Care"},{"key":"2026082209063216200_bib35","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomized trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026082209063216200_bib36","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"2026082209063216200_bib37","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41581-025-01042-0","article-title":"Next-generation therapeutics for diabetic kidney disease","volume":"22","author":"Yi","year":"2026","journal-title":"Nat Rev Nephrol"},{"key":"2026082209063216200_bib38","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2026082209063216200_bib39","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026082209063216200_bib40","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026082209063216200_bib41","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2604625","article-title":"Finerenone in persons with chronic kidney disease without diabetes","volume":"395","author":"Heerspink","year":"2026","journal-title":"N Engl J Med"},{"key":"2026082209063216200_bib42","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1016\/S0140-6736(26)01009-3","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)","volume":"407","author":"Neuen","year":"2026","journal-title":"Lancet"},{"key":"2026082209063216200_bib43","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"2026082209063216200_bib44","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1681\/ASN.0000000752","article-title":"Rapid and simultaneous initiation of guideline-directed kidney therapies in patients with CKD and type 2 diabetes","volume":"36","author":"Rashid","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"2026082209063216200_bib45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13668-025-00649-w","article-title":"Impact of GLP- 1 receptor agonist therapy in patients high risk for sarcopenia","volume":"14","author":"Memel","year":"2025","journal-title":"Curr Nutr Rep"},{"key":"2026082209063216200_bib46","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical implications of an acute dip in eGFR after SGLT2-inhibitor initiation","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026082209063216200_bib47","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1002\/edm2.360","article-title":"Potassium management with finerenone: practical aspects","volume":"5","author":"Wanner","year":"2022","journal-title":"Endocrinol Diabetes Metab"},{"key":"2026082209063216200_bib48","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.126.27036","article-title":"Safety and synergy of finerenone and empagliflozin in lowering blood pressure","author":"Agarwal","year":"2026","journal-title":"Hypertension"},{"key":"2026082209063216200_bib49","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s00125-019-4839-8","article-title":"Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS program","volume":"62","author":"Matthews","year":"2019","journal-title":"Diabetologia"},{"key":"2026082209063216200_bib50","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.2337\/dc26-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"2026082209063216200_bib51","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2-inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Med"},{"key":"2026082209063216200_bib52","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1093\/ndt\/gfaf064","article-title":"Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD","volume":"40","author":"Chuang","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026082209063216200_bib53","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/ckj\/sfad139","article-title":"Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)","volume":"16","author":"Sarafidis","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026082209063216200_bib54","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026082209063216200_bib55","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa2512854","article-title":"Finerenone in type 1 diabetes and chronic kidney disease","volume":"394","author":"Heerspink","year":"2026","journal-title":"N Engl J Med"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag179\/70556243\/gfag179.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag179\/70556243\/gfag179.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T13:06:37Z","timestamp":1787403997000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article\/doi\/10.1093\/ndt\/gfag179\/8756926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":55,"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag179","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"article-number":"gfag179"}}